{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:04:11Z","timestamp":1761609851211,"version":"3.32.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1136\/ard.2003.015933","type":"journal-article","created":{"date-parts":[[2004,1,13]],"date-time":"2004-01-13T20:08:12Z","timestamp":1074024492000},"page":"144-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit"],"prefix":"10.1016","volume":"63","author":[{"given":"P","family":"Sidiropoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H D","family":"Kritikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kouroumali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Voudouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D T","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2003.015933_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/art.10705","article-title":"Survival in rheumatoid arthritis. a population based analysis over 40 years","volume":"48","author":"Gabriel","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.015933_bib2","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2003.015933_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2003.015933_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.015933_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.015933_bib6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.015933_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.015933_bib8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comments]","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"suppl II","key":"10.1136\/ard.2003.015933_bib9","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/ard.61.suppl_2.ii2","article-title":"Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)","volume":"61","author":"Furst","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.015933_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s003930050059","article-title":"Limitations of randomized controlled clinical trials to depict accurately long-term outcomes in rheumatoid arthritis","volume":"57","author":"Pincus","year":"1998","journal-title":"Z Rheumatol"},{"key":"10.1136\/ard.2003.015933_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.015933_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.015933_bib13","first-page":"1008","article-title":"Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies","volume":"18","author":"Hawley","year":"1991","journal-title":"J Rheumatol"},{"issue":"suppl I","key":"10.1136\/ard.2003.015933_bib14","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1136\/ard.59.suppl_1.i28","article-title":"Clinical outcome measures in rheumatoid arthritis","volume":"59","author":"van Riel","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.015933_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","article-title":"Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden","volume":"61","author":"Geborek","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.015933_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2003.015933_bib17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/41.6.638","article-title":"Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha","volume":"41","author":"Den Broeder","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2003.015933_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2003.015933_bib19","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L","article-title":"The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis","volume":"44","author":"Welsing","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.015933_bib20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/41.6.601","article-title":"The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?","volume":"41","author":"Fransen","year":"2002","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724085492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724085492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2003.015933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T08:22:15Z","timestamp":1736065335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724085492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0003496724085492"],"URL":"https:\/\/doi.org\/10.1136\/ard.2003.015933","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2003.015933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Copyright 2004 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}